29 June 2020

New estimates suggest that the value of the pharmaceutical market for acute myeloid leukaemia (AML) will reach 5.1bn US dollars by 2029.

The growth will be largely due to new drugs and label expansions, the approval of current drugs for further conditions beyond original use, according to analysts.

The forecast has been made by GlobalData, the data analytics company. They published their report, “Acute Myeloid Leukemia: Opportunity Analysis and Forecasts to 2029”, on 19th June.

It suggests that the AML market will grow from $1.4bn in 2019 to $5.1bn by 2029. This expected revenue covers the eight major markets: the US, France, Germany, Italy, Spain, UK, Japan, and China.

“The management of acute myeloid leukaemia was revolutionised after 2017, mostly with the introduction of targeted agents with good efficacy and tolerability,” says Sakis Paliouras, Oncology Analyst at GlobalData.

“The treatment of older patients who cannot tolerate intensive chemotherapy has been improved and patients who relapse after initial therapy have new options available if they present with FLT3 or IDH1/2 mutations.”

GlobalData also released a report, on 21st June, on the burden of myelodysplastic syndrome (MDS) in the eight major markets. They estimate that cases could reach 112,000 by 2028.

This represents an annual growth rate of 2.4% - rising from about 90,000 cases in 2018 to about 112,000 cases ten years later.

Their report, “Myelodysplastic Syndrome: Epidemiology Forecast to 2028”, explains that the rise is likely to be due to a moderately rising trend together with an increasing elderly population.

Bishal Bhandari, epidemiologist at GlobalData says: “With improvement in diagnostic and with reclassification of myelodysplastic syndrome, cases could rise quickly. Development of well targeted therapy is necessary to improve patient survival.”

Source: GlobalData


Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/